18th Expert Committee on the Selection and Use of Essential Medicines: Applications (Sections 1-15)
Section 1: Anaesthetics
- Anaesthesia and muscle relaxant sections (Review) -- Adults and Children
- Ether (Re-instatement) -- Adults and Children
- Midazolam (Inclusion) -- Adults and Children
- Promethazine (Deletion) -- Adults and Children
- Propofol (Inclusion) -- Adults
Section 2: Analgesics
Section 3: Antiallergics
Section 4: Antidotes
- DL-methionine (Deletion) -- Adults
- Oral iron chelation therapy (Review) -- Children
- Oral lead chelation therapy (Review) -- Children
- Sodium calcium edetate and penicillamine (Review) --- Children
- Succimer (Review) -- Children
Section 5: Anticonvulsants/antiepileptics
Section 6: Anti-infective medicines
- Antivirals (Review) -- Adults and Children
- Artesunate + amodiaquine fixed-dose combination (Inclusion) -- Adults and Children
- Darunavir (Inclusion) -- Adults and Children
- Dihydroartemisinin + piperaquine (Inclusion) -- Adults and Children
- Etravirine (Inclusion) -- Adults
- Fluoroquinolones (Review) -- Children
- Gatifloxacin (Inclusion) -- Adults and Children
- Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim (New formulation) -- Adults
- Miltefosine (Inclusion) -- Adults and Children
- Neglected tropical diseases (Review) -- Children
- Pyronaridine + artesunate fixed-dose combination (Inclusion) -- Adults and Children
- Raltegravir (Inclusion) -- Adults
- Review of the evidence for H. Pylori treatment regimens: Section 17.1 (Review) -- Adults and Children
- Sulfamethoxazole + trimethoprim (New formulation) -- Adults
Section 7: Antimigraine medicines
Section 8: Antineoplastic
- Antineoplastic, immunosuppressives and medicines used in palliative care (Review) -- Children
- Ibuprofen (Review) -- Children
- Imatinib (Inclusion) -- Children and Adolescents
- Paclitaxel and docetaxel (Inclusion) -- Adults
Section 9: Antiparkinsonism medicines
Section 10: Medicines affecting the blood
Section 11: Blood products
Section 12: Cardiovascular medicines
Section 13: Dermatological medicines
Section 14: Diagnostic agents
Section 15: Disinfectants
Contact: emlsecretariat@who.int
Medicine Access and Rational Use (MAR)
20 Avenue Appia
CH-1211 Geneva 27